SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech binary events
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI3/13/2009 3:10:09 PM
  Read Replies (1) of 295
 
10:21AM Dendreon: Biotechs are risky but Dendreon may be "Russian Roulette" - Merriman (DNDN) 3.86 +0.44 : Merriman says, DNDN is expected to release the highly anticipated Phase III data from the IMPACT study. Firm views this event as one of the most binary biotech events in a very long time. The risk profile for DNDN right now is immense, although firm still maintains their negative stance on the outcome of the IMPACT study in late stage prostate cancer. Why does firm see IMPACT failing? Though the co recently reported a blinded yet positive interim result, firm believes the late stage population enrolled in the study has the cards stacked against a positive final outcome. In short, the study has included patients with Gleason scores 8 and above, as well as patients who have become symptomatic for bone pain. Firm believes that enrolling patients with more severe disease is counter to what is now clearly known in the cancer immunotherapy space that more severe patients do not respond as well to this form of therapeutic approach.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News